Baird raised the firm’s price target on Beta Bionics (BBNX) to $23 from $17 and keeps an Outperform rating on the shares. The firm updated its model following solid Q3 results but where the MDI win-rate remains the focus.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics price target raised to $32 from $26 at Piper Sandler
- Beta Bionics Reports Strong Q3 Growth and Raises Guidance
- Beta Bionics reports Q3 EPS (33c), consensus (41c)
- Beta Bionics raises FY25 revenue view to over $96.5M from $88M-$93M prior
- Beta Bionics up 13% at $27.39 after Q3 results and guidance raise